Mission Therapeutics
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Glenn Berge Building Babraham Resear...Phone Number
+44 1223607340Website
www.missiontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Mission Therapeutics
Mission Therapeutics, located in Cambridgeshire, United Kingdom, is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases, and fibrosis.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mission Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Mission Therapeutics recently announced quarterly report
Product Launch: Get notified when Mission Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Mission Therapeutics
Check if Mission Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Mission Therapeutics is spiking on competitors!
Mission Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Mission Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Mission Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Mission Therapeutics
Compare insights from companies similar to Mission Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Mission Therapeutics
<$5M
11-50
Private
$179.6M
2011
N/A
$7.1M
11-50
Private
-
-
JR
Janet RemmelManager, Human Resources & Chief Financial Officer & Executive Assistant
Company Profile Activity
Activity Insights
Mission Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mission Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mission Therapeutics.
Mission Therapeutics financials insights
Gather financial insights about Mission Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$8.2M
2013
Series B
$32.2M
2015
Grant
$2.9M
2020
Series C
$90.7M
2024
Other Financing Round
$32.2M
2025
Other Financing Round
$13.3M
Mission Therapeutics Tech Stack
A closer look at the technologies used by Mission Therapeutics
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Funding
Project
Product Management, Compliance, Legal Affairs
Mission Therapeutics News & Media
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,[1] and no currently approved therapies for the disease which is associated with rapid decline inMission raises $13.3M for Parkinson's treatment Phase 1b trial
Mission Therapeutics raised $13.3 million to advance Parkinson's treatment MTX325 into a Phase 1b clinical trial.Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's disease candidate MTX325 through clinical trials
Financing will support the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson's disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment for PD, in healthy volunteers...Mission Therapeutics announces publication in Nature Reviews Drug Discovery of article highlighting how neurodegenerative diseases can be tackled by enhancing mitophagy
Review article in high impact journal outlines the evidence that neurodegenerative diseases –including Parkinson's, Alzheimer's, ALS and Huntington's – can be addressed by boosting mitophagy, the quality control system cells use to remove dysfunctional mitochondria Strong evidence has...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mission Therapeutics
Sign Up For FreeTo access detailed company insights
Mission Therapeutics, located in Cambridgeshire, United Kingdom, is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases, and fibrosis.... Read More
